isoxazoles has been researched along with win 54954 in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.56) | 18.7374 |
| 1990's | 15 (83.33) | 18.2507 |
| 2000's | 2 (11.11) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| See, DM; Tilles, JG | 2 |
| Akullian, V; Bailey, TR; Carabateas, PM; Cutcliffe, D; Diana, GD; Eissenstat, MA; Kowalczyk, PJ; Mallamo, JP; Pevear, DC | 1 |
| Charman, SA; Charman, WN; Dutko, FJ; Pouton, CW; Rogge, MC; Wilson, TD | 1 |
| Diana, GD; Dutko, FJ; Fox, MP; McKinlay, MA | 1 |
| Diana, GD; Dutko, FJ; McKinlay, MA; Otto, MJ; Rogge, MC; Woods, MG | 1 |
| Aldi, C; Aldous, DJ; Aldous, SC; Diana, GD; Draper, T; Dutko, FJ; Nitz, TJ; Pevear, DC; Robinson, DT; Rudewicz, P | 1 |
| Bailey, TR; Cutcliffe, D; Diana, GD; Giranda, V; Mallamo, JP; Nitz, TJ; Oglesby, RC; Vescio, N; Volkots, DL; Wetzel, J | 1 |
| Andries, K; Chapman, MS; Diana, GD; Gong, ZX; Kim, KH; Kremer, MJ; Minor, I; Oliveira, MA; Rossmann, MG; Willingmann, P | 1 |
| Dutko, FJ; Goldstein, NH; Hayden, FG; Lockwood, G; Turner, RB | 1 |
| Fohlman, J; Friman, G; Ilbäck, NG; Pauksen, K; Stålhandske, T; Wesslén, L | 1 |
| Fohlman, J; Friman, G; Ilbäck, NG; Pauksen, K | 1 |
| Eggertsen, G; Ehrnst, A; Fohlman, J; Friman, G; Hyypiä, T; Ilbäck, NG; Pauksen, K | 1 |
| Borcherding, WR; Dick, EC; Galagan, DM; Gern, JE; Joseph, B | 1 |
| Grumbach, IM; Heim, A; Müller, G; Pfetzing, U | 1 |
| Heino, J; Huttunen, P; Hyypiä, T; Nissinen, L; Vihinen, P | 1 |
| Fohlman, J; Harvala, H; Hyypiä, T; Ilbäck, NG; Kytö, V; Saraste, A; Vuorinen, T | 1 |
| Egan, JA; Filer, CN; Nugent, RP | 1 |
2 trial(s) available for isoxazoles and win 54954
| Article | Year |
|---|---|
Self-emulsifying drug delivery systems: formulation and biopharmaceutic evaluation of an investigational lipophilic compound.
Topics: Administration, Oral; Animals; Capsules; Dogs; Drug Delivery Systems; Drug Evaluation, Preclinical; Drugs, Investigational; Excipients; Gelatin; Injections, Intravenous; Isoxazoles; Lipids; Male; Particle Size; Polyethylene Glycols; Postural Balance | 1992 |
Efficacy of oral WIN 54954 for prophylaxis of experimental rhinovirus infection.
Topics: Adult; Antiviral Agents; Double-Blind Method; Humans; Isoxazoles; Middle Aged; Picornaviridae Infections; Rhinovirus | 1993 |
16 other study(ies) available for isoxazoles and win 54954
| Article | Year |
|---|---|
Treatment of Coxsackievirus A9 myocarditis in mice with WIN 54954.
Topics: Animals; Antiviral Agents; Coxsackievirus Infections; Enterovirus; Isoxazoles; Male; Mice; Myocarditis; Myocardium; Organ Size | 1992 |
Antirhinoviral activity of heterocyclic analogs of Win 54954.
Topics: Antiviral Agents; Chemical Phenomena; Chemistry, Physical; Electrochemistry; Isoxazoles; Molecular Structure; Rhinovirus; Structure-Activity Relationship; Tetrazoles | 1992 |
Binding affinities of structurally related human rhinovirus capsid-binding compounds are related to their activities against human rhinovirus type 14.
Topics: Antiviral Agents; Capsid; Cells, Cultured; Dose-Response Relationship, Drug; Half-Life; Humans; Isoxazoles; Kinetics; Microbial Sensitivity Tests; Rhinovirus | 1991 |
In vitro and in vivo activities of WIN 54954, a new broad-spectrum antipicornavirus drug.
Topics: Animals; Animals, Suckling; Antiviral Agents; Coxsackievirus Infections; Culture Media; Echovirus Infections; Female; Isoxazoles; Mice; Mice, Inbred ICR; Oxazoles; Picornaviridae; Rhinovirus; Viral Plaque Assay; Virus Replication | 1989 |
Picornavirus inhibitors: trifluoromethyl substitution provides a global protective effect against hepatic metabolism.
Topics: Animals; Antiviral Agents; Chlorofluorocarbons, Methane; Chromatography, High Pressure Liquid; Computer Graphics; Haplorhini; Isoxazoles; Magnetic Resonance Spectroscopy; Mass Spectrometry; Microsomes, Liver; Picornaviridae; Spectrophotometry, Infrared | 1995 |
WIN 54954 treatment of mice infected with a diabetogenic strain of group B coxsackievirus.
Topics: Animals; Antiviral Agents; Autoantibodies; Base Sequence; Coxsackievirus Infections; Diabetes Mellitus, Experimental; Enterovirus B, Human; Glucose Tolerance Test; Insulin; Islets of Langerhans; Isoxazoles; Male; Mice; Mice, Inbred Strains; Microbial Sensitivity Tests; Molecular Sequence Data; Pancreas; RNA, Viral; Time Factors | 1993 |
Antipicornavirus activity of tetrazole analogues related to disoxaril.
Topics: Amino Acid Sequence; Antiviral Agents; Binding Sites; Humans; Isoxazoles; Microbial Sensitivity Tests; Molecular Sequence Data; Picornaviridae; Rhinovirus; Structure-Activity Relationship; Tetrazoles | 1993 |
A comparison of the anti-rhinoviral drug binding pocket in HRV14 and HRV1A.
Topics: Amino Acid Sequence; Antiviral Agents; Binding Sites; Capsid; Conserved Sequence; Drug Design; Isoxazoles; Models, Molecular; Molecular Sequence Data; Pyridazines; Rhinovirus; Sequence Alignment; Serotyping; Structure-Activity Relationship | 1993 |
Effects of the antiviral WIN 54954 and the immune modulator LS 2616 on cachectin/TNF and gamma-interferon responses during viral heart disease.
Topics: Adjuvants, Immunologic; Animals; Antiviral Agents; Coxsackievirus Infections; Enterovirus B, Human; Female; Hydroxyquinolines; Interferon-gamma; Isoxazoles; Mice; Mice, Inbred BALB C; Myocarditis; Tumor Necrosis Factor-alpha | 1993 |
Therapy of coxsackie virus B3-induced myocarditis with WIN 54954 in different formulations.
Topics: Animals; Antiviral Agents; Coxsackievirus Infections; Dosage Forms; Enterovirus B, Human; Female; Isoxazoles; Mice; Mice, Inbred BALB C; Myocarditis; Pharmaceutical Vehicles | 1993 |
Antiviral treatment with WIN 54 954 reduces mortality in murine coxsackievirus B3 myocarditis.
Topics: Animals; Antibodies, Viral; Antiviral Agents; Blotting, Northern; Complement C3; Complement Factor B; Complement System Proteins; Coxsackievirus Infections; Enterovirus; Enterovirus B, Human; Isoxazoles; Male; Mice; Mice, Inbred A; Mice, Inbred BALB C; Mice, Inbred CBA; Myocarditis; Neutralization Tests; RNA, Messenger; Survival Analysis | 1996 |
Rhinovirus inhibits antigen-specific T cell proliferation through an intercellular adhesion molecule-1-dependent mechanism.
Topics: Antigen Presentation; Antigens, Viral; Antiviral Agents; Cells, Cultured; Chickenpox; Cytotoxicity, Immunologic; HeLa Cells; Humans; Intercellular Adhesion Molecule-1; Interleukin-2; Isoxazoles; Killer Cells, Natural; Leukocytes, Mononuclear; Lymphocyte Activation; Mitogens; Picornaviridae Infections; Pollen; Protein Binding; Rhinovirus; Streptokinase; T-Lymphocytes; Tetanus Toxoid; Tumor Necrosis Factor-alpha | 1996 |
Antiviral activity of WIN 54954 in coxsackievirus B2 carrier state infected human myocardial fibroblasts.
Topics: Animals; Antiviral Agents; Carrier State; Cells, Cultured; Chlorocebus aethiops; Coxsackievirus Infections; Dose-Response Relationship, Drug; Enterovirus B, Human; Fibroblasts; Heart; Humans; In Situ Hybridization; Isoxazoles; Polymerase Chain Reaction; RNA-Directed DNA Polymerase; Vero Cells; Viral Plaque Assay; Virus Replication | 1998 |
Echovirus 1 infection induces both stress- and growth-activated mitogen-activated protein kinase pathways and regulates the transcription of cellular immediate-early genes.
Topics: Animals; Antiviral Agents; Calcium-Calmodulin-Dependent Protein Kinases; Cell Adhesion; Collagen; Enterovirus B, Human; Enzyme Inhibitors; Gene Expression Regulation, Viral; Genes, Immediate-Early; Haplorhini; Humans; Isoxazoles; Kidney; Phosphorylation; Poliovirus; Protein Biosynthesis; Proto-Oncogenes; Receptors, Virus; RNA, Messenger; Sarcoma, Experimental; Semliki forest virus; Transcription Factor AP-1; Transcription, Genetic; Tumor Cells, Cultured | 1998 |
Cardiomyocyte apoptosis after antiviral WIN 54954 treatment in murine coxsackievirus B3 myocarditis.
Topics: Animals; Antiviral Agents; Apoptosis; Enterovirus B, Human; Enterovirus Infections; Heart Ventricles; Isoxazoles; Mice; Mice, Inbred Strains; Myocarditis; Myocardium; Necrosis | 2002 |
Potent antiviral agent WIN 54954: high specific activity labelling with tritium.
Topics: Antiviral Agents; Indicators and Reagents; Isoxazoles; Radioisotope Dilution Technique; Tritium | 2004 |